share_log

GlaxoSmithKline | 6-K: Strong Year-to-Date and Q3 Performance Drives Upgrade to Full-Year Guidance

SEC announcement ·  Nov 2, 2023 00:51
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.